Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis

@article{Banerji2017InhibitingPK,
  title={Inhibiting Plasma Kallikrein for Hereditary Angioedema Prophylaxis},
  author={Aleena Banerji and Paula J Busse and Mustafa Shennak and William R Lumry and Mark A Davis-Lorton and H. James Wedner and Joshua J. Jacobs and James Baker and Jonathan A. Bernstein and Richard F. Lockey and Henry H. Li and Timothy Craig and Marco Cicardi and Marc A. Riedl and Ahmad Al-Ghazawi and Carolyn Soo and Ryan Iarrobino and Daniel J. Sexton and Christopher Tenhoor and Jon A. Kenniston and Ryan R. Faucette and Gordon J. Still and Harvey W Kushner and Robert K. Mensah and Chris Stevens and Joseph C. Biedenkapp and Yung H Chyung and Burt Adelman},
  journal={The New England Journal of Medicine},
  year={2017},
  volume={376},
  pages={717–728}
}
Background Hereditary angioedema with C1 inhibitor deficiency is characterized by recurrent, unpredictable swelling episodes caused by uncontrolled plasma kallikrein generation and excessive bradykinin release resulting from cleavage of high‐molecular‐weight kininogen. Lanadelumab (DX‐2930) is a new kallikrein inhibitor with the potential for prophylactic treatment of hereditary angioedema with C1 inhibitor deficiency. Methods We conducted a phase 1b, multicenter, double‐blind, placebo… 

Figures and Tables from this paper

A review of kallikrein inhibitor lanadelumab in hereditary angioedema.

Lanadelumab (DX-2930, SHP-643), a recombinant, fully human IgG1 monoclonal antibody kallikrein inhibitor, is a new prophylactic drug for hereditary angioedema with C1 esterase inhibitor deficiency.

Pharmacokinetics, Pharmacodynamics, and Exposure‐Response of Lanadelumab for Hereditary Angioedema

Exposure‐response analyses suggest that 300 mg Q2W dosing was associated with a significantly reduced HAE attack rate, prolonged time to first attack after treatment initiation, and lower need for concomitant medications.

Kallikrein Inhibition for Hereditary Angioedema.

Lanadelumab is a recombinant fully human monoclonal antibody and the first therapeutic agent to allow sustained inhibition of kallikrein, a central role in the generation of inflammation and pain in angioedema.

Lanadelumab for the prevention of attacks in hereditary angioedema

This review provides an overview of lanadelumab, a human monoclonal antibody targeted against plasma kallikrein that was recently approved for prevention of symptoms in C1-INH-HAE, and addresses some of the limitations of existing prophylactic options.

Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients

  • H. Farkas
  • Medicine, Biology
    Pediatric Drugs
  • 2017
This review summarizes the properties of the medicinal products currently available for the treatment of C1-INH-HAE, the indications for their use in pediatric patients, and the findings of the clinical trials conducted in this patient population.

Effect of Lanadelumab Compared With Placebo on Prevention of Hereditary Angioedema Attacks: A Randomized Clinical Trial

Findings support the use of lanadelumab as a prophylactic therapy for hereditary angioedema and further research is needed to determine long-term safety and efficacy.

Hereditary Angioedema: Diagnosis, Pathogenesis, and Therapy

  • A. Kaplan
  • Biology, Medicine
    Current Treatment Options in Allergy
  • 2022
A new emphasis on the therapeutic efficacy of transexamic acid and progesterone is associated with HAEN while therapy of types I and II HAE (C1 inhibitor deficiency) have new approaches including administration of subcutaneous C1 INH, or a monoclonal antibody to plasma kallikrein, and an oral once-daily kallkrein inhibitor.

Lanadelumab for the treatment of hereditary angioedema

  • M. Wu
  • Medicine, Biology
    Expert opinion on biological therapy
  • 2019
Lanadelumab is able to inhibit plasma kallikrein with high selectivity and affinity and overcomes some of the limitations of other drugs available for long-term prophylaxis, given the easy route of administration, the simple administration schedule and the possibility to tailor the treatment to each patient.

Oral plasma kallikrein inhibitor BCX7353 for treatment of hereditary angioedema.

Overall, results indicate BCX7353 is a promising form of therapy with a rapid 1 h onset of action, long duration ofaction, and acceptable tolerance.

Kallikrein Inhibition for Hereditary Angioedema.

Encouraging results from the use of lanadelumab for the prevention of angioedema associated with C1 inhibitor deficiency promise a major step toward achieving independence from ongoing medical care for all affected by the disorder.
...

References

SHOWING 1-10 OF 38 REFERENCES

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients.

  • K. BorkA. BygumJ. Hardt
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2008

The bradykinin-forming cascade and its role in hereditary angioedema.

  • A. KaplanK. Joseph
  • Medicine, Biology
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2010

Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema.

Treatment of Hereditary Angioedema with Danazol

Danazol effectively prevents attacks in hereditary angioedema and acts to correct the underlying biochemical abnormality and side effects were minimal.

Ecallantide for treatment of acute attacks of hereditary angioedema.

Ecallantide is a novel agent approved for the treatment of acute attacks of HAE at any anatomical site, presents a unique mechanism of action, and appears to be safe and effective when used for its labeled indication.

Inhibition of Plasma Kallikrein by a Highly Specific Active Site Blocking Antibody

A potent and long acting inhibitor of pKal activity could be an effective treatment option for pKal-mediated diseases, such as HAE.

Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities.

Danazol effectively prevents attacks in hereditary angioedema and acts to correct the underlying biochemical abnormality and side effects were minimal.

Nanofiltered C1 Inhibitor Concentrate for Treatment of Hereditary Angioedema

The aim of this study was to determine the efficacy of nanofiltered C1 inhibitor concentrate in the management of hereditary angioedema.

A phase 1 study investigating DX-2930 in healthy subjects.

  • Y. ChyungB. Vince B. Adelman
  • Medicine
    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
  • 2014

Plasma kallikrein: novel functions for an old protease.

This animal model provides a promising tool to study the pathogenetic role of the protease in models of thrombosis and inflammation with exciting therapeutic perspectives and hereditary deficiencies in PK and its substrate HK were not associated with haemostatic abnormalities.